Looking Into the Future of Lipid Management
Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia
Read More
How to Select Between Available LDL-C Lowering Therapies
Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia
Clinical Trial Results on Novel Nonstatins Agents.
Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.
Mechanism of Action of Nonstatin Therapies
Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.
The Cumulative Burden of LDL-C
Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.
Overcoming Access Barriers to Novel Non Statin Therapies
Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.
Combination Therapy in LDL Lowering
Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients
Nonstatin Agents for LDL-C Lowering
Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.
How Low is Too Low in LDL-C?
Expert cardiologists discuss if there is such a thing as an LDL that is a too low.
Matching the Intensity of Treatment to Cardiovascular Risk
Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.
Assessing Cardiovascular Risk in Your Patients
Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.
Clinical Pearls on Lipid Management
A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.
Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy
Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.
The Role of Lipoprotein A in Lipid Lowering
Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.
Long-term efficacy and safety of PCSK9 inhibitors
Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.
Starting Combination Therapy Early
The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.
Nonstatin Lipid-Lowering Agents
Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.
Statin Intolerance
Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.
Disparities in Managing Patients
Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.
LDL Cholesterol as a Performance Measure
The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.
Reasons for Not Reaching Thresholds
The reasons many patients do not reach LDL-cholesterol thresholds.
Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds
Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.
Real-World Data on Achieving LDL Thresholds
Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.
New Guidance in Lowering LDL-C
A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.
LDL-C and Cardiovascular Disease Risk
Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.